Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study

References

• Ezzeddine Z, Ghssein G. Towards new antibiotics classes targeting bacterial metallophores. Microb Pathog. 2023;182:106221. doi:10.1016/j.micpath.2023.106221
   PubMed Web of Science ®Google Scholar
• Logan LK, Renschler JP, Gandra S, et al. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999–2012. Emerg Infect Dis. 2015;21(11):2014–2021. doi:10.3201/eid2111.150548
   PubMed Web of Science ®Google Scholar
• Logan LK, Gandra S, Mandal S, et al. Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United States, 1999–2012. J Pediatric Infect Dis Soc. 2017;6(4):352–359. doi:10.1093/jpids/piw064
   PubMed Web of Science ®Google Scholar
• Logan LK, Gandra S, Trett A, Weinstein RA, Laxminarayan R. Acinetobacter baumannii resistance trends in children in the United States, 1999–2012. J Pediatric Infect Dis Soc. 2019;8(2):136–142. doi:10.1093/jpids/piy018
   PubMed Web of Science ®Google Scholar
• Caselli D, Cesaro S, Fagioli F, et al. Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in Italy. Infect Dis. 2016;48(2):152–155. doi:10.3109/23744235.2015.1087647
   PubMed Web of Science ®Google Scholar
• Montagnani C, Prato M, Scolfaro C, et al. Carbapenem-resistant Enterobacteriaceae infections in children: an Italian Retrospective Multicenter Study. Pediatr Infect Dis J. 2016;35(8):862–868. doi:10.1097/INF.0000000000001188
   PubMed Web of Science ®Google Scholar
• Alvares PA, Arnoni MV, da Silva CB, Safadi MAP, Mimica MJ. Carbapenem-resistant Gram-negative bloodstream infections in critically ill children: outcome and risk factors in a tertiary teaching hospital in South America. J Hosp Infect. 2019;101(2):188–189. doi:10.1016/j.jhin.2018.10.001
   PubMed Web of Science ®Google Scholar
• Chiotos K, Tamma PD, Flett KB, et al. Increased 30-day mortality associated with carbapenem-resistant Enterobacteriaceae in children. Open Forum Infect Dis. 2018;5(10):ofy222. doi:10.1093/ofid/ofy222
   PubMed Web of Science ®Google Scholar
• Dong F, Zhang Y, Yao K, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in a Chinese Children’s Hospital: predominance of New Delhi Metallo-beta-Lactamase-1. Microb Drug Resist. 2018;24(2):154–160. doi:10.1089/mdr.2017.0031
   PubMed Web of Science ®Google Scholar
• Nabarro LEB, Shankar C, Pragasam AK, et al. Clinical and bacterial risk factors for mortality in children with carbapenem-resistant Enterobacteriaceae bloodstream infections in India. Pediatr Infect Dis J. 2017;36(6):e161–e166. doi:10.1097/INF.0000000000001499
   PubMed Web of Science ®Google Scholar
• Logan LK, Bonomo RA. Metallo-beta-Lactamase (MBL)-producing Enterobacteriaceae in United States Children. Open Forum Infect Dis. 2016;3(2):ofw090. doi:10.1093/ofid/ofw090
   PubMed Web of Science ®Google Scholar
• Maltezou HC, Kontopidou F, Katerelos P, Daikos G, Roilides E, Theodoridou M. Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children. Pediatr Infect Dis J. 2013;32(4):e151–e154. doi:10.1097/INF.0b013e3182804b49
   PubMed Web of Science ®Google Scholar
• Diaz A, Ortiz DC, Trujillo M, Garces C, Jaimes F, Restrepo AV. Clinical characteristics of carbapenem-resistant Klebsiella pneumoniae infections in ill and colonized children in Colombia. Pediatr Infect Dis J. 2016;35(3):237–241. doi:10.1097/INF.0000000000000987
   PubMed Web of Science ®Google Scholar
• Taoufik L, Amrani Hanchi A, Fatiha B, Nissrine S, Mrabih Rabou MF, Nabila S. Emergence of OXA-48 Carbapenemase Producing Klebsiella pneumoniae in a Neonatal Intensive Care Unit in Marrakech, Morocco. Clin Med Insights Pediatr. 2019;13:1179556519834524. doi:10.1177/1179556519834524
   Google Scholar
• Madney Y, Aboubakr S, Khedr R, et al. Carbapenem-Resistant Enterobacteriaceae (CRE) among children with cancer: predictors of mortality and treatment outcome. Antibiotics. 2023;12(2):405. doi:10.3390/antibiotics12020405
   Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy492
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):10–128. doi:10.1128/aac.00883-17
   Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Almangour TA, Ghonem L, Aljabri A, et al. Ceftazidime-avibactam versus colistin for the treatment of infections due to carbapenem-resistant Enterobacterales: a multicenter cohort study. Infect Drug Resist. 2022;15:211–221. doi:10.2147/IDR.S349004
   PubMed Web of Science ®Google Scholar
• Ji Z, Sun K, Li Z, Cheng W, Yang J. Carbapenem-resistant Klebsiella pneumoniae osteomyelitis treated with ceftazidime-avibactam in an infant: a case report. Infect Drug Resist. 2021;14:3109–3113. doi:10.2147/IDR.S320056
   PubMed Web of Science ®Google Scholar
• Wang W, Wang R, Zhang Y, et al. Ceftazidime-avibactam as salvage therapy in pediatric liver transplantation patients with Infections caused by carbapenem-resistant enterobacterales. Infect Drug Resist. 2022;15:3323–3332. doi:10.2147/IDR.S369368
   PubMed Web of Science ®Google Scholar
• Iosifidis E, Chorafa E, Agakidou E, et al. Use of Ceftazidime-avibactam for the treatment of extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age. Pediatr Infect Dis J. 2019;38(8):812–815. doi:10.1097/INF.0000000000002344
   PubMed Web of Science ®Google Scholar
• Perruccio K, Rosaria D, Amico M, et al. Ceftolozane/Tazobactam and Ceftazidime/Avibactam: an Italian Multi-center retrospective analysis of safety and efficacy in children with hematologic malignancies and multi-drug resistant gram-negative bacteria infections. Pediatr Infect Dis J. 2022;41(12):994–996. doi:10.1097/INF.0000000000003716
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0; 2020. Available from: http://www.eucast.org. Accessed August 30, 2023.
   Google Scholar
• Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st edition. J Clin Microbiol. 2021;59(12):e0021321. doi:10.1128/JCM.00213-21
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: CLSI Supplement M100-S28 [S]. 28th ed. Wayne PA: Clinical and Laboratory Standards Institute; 2018:112–122.
   Google Scholar
• Iovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. Clin Lab Med. 2017;37(2):303–315. doi:10.1016/j.cll.2017.01.005
   PubMed Web of Science ®Google Scholar
• Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80. doi:10.3389/fmicb.2019.00080
   PubMed Web of Science ®Google Scholar
• Sokhn ES, Salami A, El Roz A, Salloum L, Bahmad HF, Ghssein G. Antimicrobial susceptibilities and laboratory profiles of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates as agents of urinary tract infection in Lebanon: paving the way for better diagnostics. Med Sci. 2020;8(3):32. doi:10.3390/medsci8030032
   Google Scholar
• Jia X, Yin Z, Zhang W, Guo C, Du S, Zhang X. Effectiveness and nephrotoxicity of intravenous polymyxin B in carbapenem-resistant gram-negative bacterial infections among Chinese children. Front Pharmacol. 2022;13:902054. doi:10.3389/fphar.2022.902054
   PubMed Web of Science ®Google Scholar
• Ustundag G, Oncel EK, Sahin A, Keles YE, Aksay AK, Ciftdogan DY. Colistin treatment for multidrug-resistant gram-negative infections in children: caution required for nephrotoxicity. Sisli Etfal Hastan Tip Bul. 2022;56(3):427–434. doi:10.14744/SEMB.2021.69851
   PubMed Web of Science ®Google Scholar
• Sahbudak Bal Z, Kamit Can F, Yazici P, et al. The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: results from two reference hospitals and review of literature. J Infect Chemother. 2018;24(5):370–375. doi:10.1016/j.jiac.2017.12.017
   PubMed Web of Science ®Google Scholar
• Siddiqui NU, Qamar FN, Jurair H, Haque A. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. BMC Infect Dis. 2014;14:626. doi:10.1186/s12879-014-0626-9
   PubMed Web of Science ®Google Scholar
• Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.00314
   PubMed Web of Science ®Google Scholar
• Pannaraj PS, Bard JD, Cerini C, Weissman SJ. Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States. Pediatr Infect Dis J. 2015;34(1):11–16. doi:10.1097/INF.0000000000000471
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Carbonara S, et al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram negative bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis. 2023;76(12):2059–2069.
   PubMed Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of Ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by Metallo-beta-lactamase-producing enterobacterales. Clin Infect Dis. 2021;72(11):1871–1878. doi:10.1093/cid/ciaa586
   PubMed Web of Science ®Google Scholar
• Shields RK, Doi Y. Aztreonam combination therapy: an answer to Metallo-beta-Lactamase-producing gram-negative bacteria? Clin Infect Dis. 2020;71(4):1099–1101. doi:10.1093/cid/ciz1159
   PubMed Web of Science ®Google Scholar
• Zheng G, Zhang J, Wang B, et al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021;10(3):1699–1713. doi:10.1007/s40121-021-00479-7
   PubMed Web of Science ®Google Scholar
• Meng H, Yang J, Niu M, Zhu H, Zhou Y, Lu J. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in children: a retrospective study. Int J Antimicrob Agents. 2023;106933. doi:10.1016/j.ijantimicag.2023.106933
   PubMedGoogle Scholar
• Radha S, Warrier AR, Wilson A, Prakash S. Use of ceftazidime-avibactam in the treatment of clinical syndromes with limited treatment options: a retrospective study. Cureus. 2023;15(1):e33623. doi:10.7759/cureus.33623
   PubMed Web of Science ®Google Scholar
• Lin Q, Wang Y, Yu J, et al. Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection. BMC Infect Dis. 2021;21(1):638. doi:10.1186/s12879-021-06315-0
   PubMed Web of Science ®Google Scholar
• Dickstein Y, Edelman R, Dror T, Hussein K, Bar-Lavie Y, Paul M. Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers. J Hosp Infect. 2016;94(1):54–59. doi:10.1016/j.jhin.2016.05.018
   PubMed Web of Science ®Google Scholar
• Daikos GL, Vryonis E, Psichogiou M, et al. Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase. J Antimicrob Chemother. 2010;65(4):784–788. doi:10.1093/jac/dkq005
   PubMed Web of Science ®Google Scholar